ElevateBio is a technology company.
ElevateBio has raised $930.0M across 2 funding rounds.
ElevateBio has raised $930.0M in total across 2 funding rounds.
ElevateBio has raised $930.0M in total across 2 funding rounds.
ElevateBio's investors include MPM Capital, RA Capital, Stuart Peterson, Cisco Investments, DFJ, Kevin Ding, Felicis Ventures, Foundation Capital, General Catalyst, Madrona Ventures, Next47, Sequoia Capital.
ElevateBio is a technology-driven biotechnology company that powers the development and manufacturing of transformative cell and gene therapies, known as genetic medicines.[1][2][4] It builds an integrated ecosystem combining R&D platforms like Life Edit—a next-generation gene editing toolbox—and BaseCamp, its end-to-end cGMP manufacturing and process development business, to accelerate therapies from concept to commercialization for partners targeting diseases such as cancer, genetic disorders, and infectious conditions.[1][2][3][4] Serving biopharma companies and internal programs, ElevateBio solves key bottlenecks in the industry by de-risking development through unified technologies (e.g., ex vivo/in vivo therapies, viral/non-viral delivery, lipid nanoparticles), cutting-edge manufacturing, and AI-driven insights, enabling faster delivery of potentially curative treatments.[2][3][5][7]
ElevateBio was founded over seven years ago (around 2018 or earlier) to redefine genetic medicine development beyond traditional biotech or contract manufacturing models, creating a "genetic medicine foundry" with fully integrated tech stacks and end-to-end capabilities.[3][6] Key figures include industry-leading experts in gene editing, cellular engineering, and manufacturing, though specific founders are not detailed in available sources; the company has assembled top talent with hands-on experience in cell/gene therapy discovery and production.[2][6][8] Early traction came from building world-class facilities, diverse platforms (e.g., gene editing, iPSCs, protein/viral engineering), and BaseCamp as a centralized hub, positioning it to bridge discovery gaps and support rapid innovation amid rising demand for scalable therapies.[3][6]
ElevateBio stands out through its foundry model, the first fully integrated stack combining R&D technologies and manufacturing:
ElevateBio rides the explosive growth of cell and gene therapy, a trend shifting medicine toward curative genetic interventions for untreatable diseases, fueled by CRISPR advancements and manufacturing scalability needs.[1][3][4] Timing is ideal amid regulatory approvals, biopharma investments, and post-pandemic biotech momentum, where traditional models fail on speed and integration—ElevateBio's foundry addresses this "missing link" between discovery and delivery.[2][3] Market forces like enormous data from engineering processes and demands for AI-enabled efficiency favor its data architecture and emerging tech evaluations.[5][7] It influences the ecosystem by partnering with biopharma, de-risking pipelines, and standardizing high-quality manufacturing, potentially making genetic medicines "everyday" therapies.[2][4]
ElevateBio is poised to lead as genetic medicines scale, with expansions in AI-protein engineering, non-viral delivery, and automated systems driving internal pipelines and partnerships toward commercialization.[3][5][8] Trends like multiplex editing for complex disorders, digital manufacturing, and data unification will shape its path, amplifying impact as therapies target broader indications.[7][8] Its influence may evolve into a dominant platform provider, redefining biotech by embedding intelligence across the value chain and powering widespread access to regenerative cures—solidifying its role as the engine for tomorrow's medicine.[1][3]
ElevateBio has raised $930.0M across 2 funding rounds. Most recently, it raised $400.0M Series D in May 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2023 | $400.0M Series D | MPM Capital, RA Capital | |
| Mar 1, 2021 | $530.0M Series C | Stuart Peterson, Cisco Investments, DFJ, Kevin Ding, Felicis Ventures, Foundation Capital, General Catalyst, Madrona Ventures, Next47, Sequoia Capital, Wing Venture Capital |